<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU-Authors

Organization Authors

Co-Authors

Morra, Simone

Incesu, Reha-Baris

Scheipner, Lukas

Baudo, Andrea

Jannello, Letizia Maria Ippolita

Siech, Carolin

de Angelis, Mario

Tian, Zhe

Creta, Massimiliano

Califano, Gianluigi

Date

Language

Embargo Status

N/A

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Background: It is unknown whether the stage of the primary may influence the survival (OS) of metastatic upper tract urothelial carcinoma (mUTUC) patients treated with nephroureterectomy (NU) and systemic therapy (ST). We tested this hypothesis within a large-scale North American cohort. Methods: Within Surveillance Epidemiology and End Results database 2000–2020, all mUTUC patients treated with ST+NU or with ST alone were identified. Kaplan–Maier plots depicted OS. Multivariable Cox regression (MCR) models tested for differences between ST+NU and ST alone predicting overall mortality (OM). All analyses were performed in localized (T1–T2) and then repeated in locally advanced (T3–T4) patients. Results: Of all 728 mUTUC patients, 187 (26%) harbored T1–T2 vs 541 (74%) harbored T3–T4. In T1–T2 patients, the median OS was 20 months in ST+NU vs 10 months in ST alone. Moreover, in MCR analyses that also relied on 3 months’ landmark analyses, the combination of ST+NU independently predicted lower OM (HR 0.37, p < 0.001). Conversely, in T3–T4 patients, the median OS was 12 in ST+NU vs 10 months in ST alone. Moreover, in MCR analyses that also relied on 3 months’ landmark analyses, the combination of ST+NU was not independently associated with lower OM (HR 0.85, p = 0.1). Conclusions: In mUTUC patients, treated with ST, NU drastically improved survival in T1–T2 patients, even after strict methodological adjustments (multivariable and landmark analyses). However, this survival benefit did not apply to patients with locally more advanced disease (T3–T4).

Source

Publisher

Springer

Citation

item.page.haspartof

Source

World Journal of Urology

item.page.ispartofseries

item.page.edition

DOI

10.1007/s00345-024-05057-3

item.page.datauri

item.page.link

Rights

N/A

Copyrights Note

Rights and licensing

N/A

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators